Iveda Solutions Granted Additional Nasdaq Bid-Price Compliance Period

What Happened

• Iveda Solutions, Inc. (IVDA) announced that Nasdaq granted the company an additional 180‑calendar day compliance period to cure a closing bid price deficiency under Nasdaq Listing Rule 5550(a)(2). Nasdaq initially notified the company on March 6, 2026 that the closing bid had been below the $1.00 minimum; the company had until September 2, 2026 to regain compliance. After requesting more time on September 2, 2026, the company received Nasdaq’s letter on September 4, 2026 giving it until March 1, 2027 to meet the minimum $1.00 closing bid requirement.

Key Details

• Deficiency rule: Nasdaq Listing Rule 5550(a)(2) requires a $1.00 minimum closing bid price.
• Initial timeline: Notice received March 6, 2026; initial 180‑day cure period ended September 2, 2026.
• Extension granted: Additional 180 days granted on September 4, 2026, extending the deadline to March 1, 2027.
• Possible cure actions: The company said it may consider a reverse stock split if needed; Nasdaq may still delist the company during the extension for failure to meet other listing standards, and the company could appeal any delisting decision.

Why It Matters

• For investors, this filing signals an elevated risk that IVDA could be delisted from Nasdaq if the company cannot raise its share price or otherwise meet listing standards by March 1, 2027. Delisting can reduce liquidity, make trading and brokerage support more difficult, and often harms share value. A reverse stock split, if implemented, would reduce share count and raise the per‑share price but would not change the company’s market capitalization. The company provided no assurance it will regain compliance. Investors should monitor IVDA’s share price, company announcements, and any actions (such as a reverse split) that could affect trading or holdings.